Samotolisib is named as an intervention in 3 current clinical trials in our USA, Canada, Australia and Israel registers. 1 is recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Eli Lilly and Company (1). The most-studied condition is Breast Neoplasms.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
RESOLVE: Abemaciclib + Letrozole +/- Metformin or Gedatolisib in Endometrial Cancer
NCT03675893 · ClinicalTrials.gov ↗ · Endometrial Cancer
|
Phase 2 | Recruiting | Dana-Farber Cancer Institute | Israel |
|
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
NCT03155620 · ClinicalTrials.gov ↗ · Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma
|
Phase 2 | Active, closed | National Cancer Institute (NCI) | Canada, Australia |
|
A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread
NCT02057133 · ClinicalTrials.gov ↗ · Breast Neoplasms
|
Phase 1 | Active, closed | Eli Lilly and Company | USA |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Eli Lilly and Company | 1 |
| National Cancer Institute (NCI) | 1 |
| Dana-Farber Cancer Institute | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 1 | 0 |
| Clinical trials in Canada | 1 | 0 |
| Clinical trials in Australia | 1 | 0 |
| Clinical trials in Israel | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
3 current trials in our USA, Canada, Australia and Israel registers name Samotolisib (also registered as LY3023414) as a drug or biological intervention, as of the registry sync on 27 September 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 3 trials is recruiting: 1 with sites in Israel. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Eli Lilly and Company (1), National Cancer Institute (NCI) (1) and Dana-Farber Cancer Institute (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Samotolisib works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Samotolisib works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Samotolisib (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 27 Sep 2026.